Research shows that 2030% of young adults report needle fear
patients must meet qualifying criteria set through negotiations This is the largest potential expansion of obesity drug access in Medicaid history but its not automatic
The plastic in syringes is not designed for preserving peptide stability over many days, and there is a higher risk of contamination
this does not constitute a confirmed contraindication under current UK or EU guidance
Several licensed weight management injectable therapies are available in the UK including semaglutide (Wegovy, approved by NICE for weight management in eligible adults) and tirzepatide (Mounjaro, licensed in the UK for type 2 diabetes and, subject to current NICE guidance, for weight management in eligible adults)
Furthermore, in a meta-analysis study, a moderate increase in the relative risk and a slight increase in absolute risk of thyroid cancer with the use of GLP-1 agonists was reported 48